"Subpuncting" of medieval manuscripts also denotes omitted meaning and may be related.Occasionally, it would be used in pulp fiction and other works of early 20th-century fiction to denote expletives that would otherwise have been censored.An ellipsis may also imply an unstated alternative indicated by context. For example, "I never drink wine ..." implies that the speaker does drink something else—such as vodka. In reported speech, the ellipsis can be used to represent an intentional silence. In poetry, an ellipsis is used as a thought-pause or line break at the caesura or this is used to highlight sarcasm or make the reader think about the last points in the poem. In news reporting, often put inside square brackets, it is used to indicate that a quotation has been condensed for space, brevity or relevance, as in "The President said that [...] he would not be satisfied", where the exact quotation was "The President said that, for as long as this situation continued, he would not be satisfied". Herb Caen, Pulitzer-prize-winning columnist for the San Francisco Chronicle, became famous for his "three-dot journalism". In different languages
In English
American English
The Chicago Manual of Style suggests the use of an ellipsis for any omitted word, phrase, line, or paragraph from within but not at the end of a quoted passage. There are two commonly used methods of using ellipses: one uses three dots for any omission, while the second one makes a distinction between omissions within a sentence (using three dots: . . .)
Cetrorelix (INN, BAN), or cetrorelix acetate (USAN, JAN), sold under the brand name Cetrotide, is an injectable gonadotropin-releasing hormone (GnRH) antagonist. A synthetic decapeptide, it is used in assisted reproduction to inhibit premature luteinizing hormone surges The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In addition, cetrorelix can be used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). It is administered as either multiple 0.25 mg daily subcutaneous injections or as a single-dose 3 mg subcutaneous injection. The duration of the 3 mg single dose is four days; if human chorionic gonadotropin (hCG) is not administered within four days, a daily 0.25 mg dose is started and continued until hCG is administered. Medical uses
Cetrorelix is marketed by Merck Serono for use in in-vitro fertilization in all countries except Japan, where it is marketed by Shionogi and Nippon Kayaku. Aeterna Zentaris receives royalties on these sales and retains rights to develop cetrorelix for other indications. In IVF use it is injected daily after follicle stimulation has been initiated and evidence of follicle maturation is approaching; given daily it prevents an endogenous LH surge that would trigger an untimely ovulation prior to the hCG administration by the treating physician.